TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.

Saved in:
Bibliographic Details
Title: TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.
Authors: Wu B; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA lellisen@mgh.harvard.edu wu.bogang@mayo.edu.; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA., Thant W; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA.; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA., Bitman E; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Liu T; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Liu J; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA.; Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA., Paschalis EI; Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA., Patel BK; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Nawrocki C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Xu KH; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Nieman LT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Ting DT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., de Gois Macedo B; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA., Cheng Y; Department of Immunology, Mayo Clinic Arizona, Phoenix, Arizona, USA., Jiang K; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Sun F; Division of Gastrointestinal and Oncologic Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Thimmiah N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Sun S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Abelman RO; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Bossuyt VI; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Isakoff SJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Spring LM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA., Ellisen LW; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA lellisen@mgh.harvard.edu wu.bogang@mayo.edu.; Ludwig Center at Harvard, Boston, Massachusetts, USA.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2026 Apr 03; Vol. 14 (4). Date of Electronic Publication: 2026 Apr 03.
Publication Type: Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2051-1426
DOI:10.1136/jitc-2025-012265